ANNOVIS BIO (ANVS)

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). The company is headquartered in Berwyn, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-01-29. The Company’s pipeline includes Buntanetap, ANVS405 and ANVS301. Its lead product candidate Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Additionally, Buntanetap was observed to protect nerve cells from dying in the brain of traumatic brain injury mice and to protect nerve cells from dying in the eye of glaucoma rats. ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia.

Company Info

ANNOVIS BIO

1055 Westlakes Dr Ste 300

Berwyn PENNSYLVANIA 19312

P: 16107273913

CEO: Maria Maccecchini

Employees: 5

Website: https://www.annovisbio.com/